Skip to navigation Skip to content

News

Share

Case of PML Reported in Person Receiving Ocrevus to Treat MS

May 25, 2017

Reports have emerged indicating that a person with MS taking Ocrevus (ocrelizumab, Genentech, a member of the Roche Group) has developed PML (progressive multifocal leukoencephalopathy, a rare viral infection of the brain that often leads to death or severe disability). The company has confirmed that this person had received one dose of Ocrevus, and had previously taken Tysabri (natalizumab, Biogen) for several years. No additional information about the individual’s condition has been released.
 
PML is caused by the re-activation of a virus called the JC (John Cunningham) virus, a common virus to which many people have been exposed. PML has emerged in people using other MS therapies, most notably Tysabri, but it has also occurred in people taking Gilenya (fingolimod, Novartis AG) and Tecfidera (dimethyl fumarate, Biogen).

This is the first reported case of PML in someone taking Ocrevus. Because PML has occurred in people taking therapies similar to Ocrevus, this therapy’s prescribing information and medication guide contain a warning regarding the possible occurrence of PML. 
 
Symptoms of PML are diverse and can be similar to MS symptoms. For this reason individuals should be alert to any new or worsening symptoms and report them promptly to their MS healthcare provider. Learn more about the risk factors and symptoms of PML here.

Individuals who have concerns about this report should discuss it with their MS healthcare providers.

If and when there is additional information or recommendations for people taking Ocrevus or other MS medications, the National MS Society will share it as soon as possible.
 
Ocrevus is a trademark of Genentech, a member of the Roche Group.
Gilenya is a registered trademark of Novartis AG.
Tysabri is a registered trademark of Biogen.
Tecfidera is a registered trademark of Biogen.
 

About Multiple Sclerosis

Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS.

About the National Multiple Sclerosis Society

The National MS Society, founded in 1946, is the global leader of a growing movement dedicated to creating a world free of MS. The Society funds cutting-edge research for a cure, drives change through advocacy and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved: nationalMSsociety.org, Facebook, X, formerly known as Twitter, Instagram, YouTube or 1-800-344-4867.

Share


© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.